David C. Murray
Loyola University Chicago
5 Papers
17 Citations
David C. Murray is an academic researcher from Loyola University Chicago. The author has contributed to research in topics: T-cell receptor & Antigen. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors
Timothy T. Spear,Glenda G. Callender,Glenda G. Callender,Jeffrey J. Roszkowski,Kelly Moxley,Kelly Moxley,Patricia E. Simms,Kendra C. Foley,David C. Murray,Gina Scurti,Gina Scurti,Mingli Li,Justin T. Thomas,Alexander Langerman,Elizabeth Garrett-Mayer,Yi Zhang,Yi Zhang,Michael I. Nishimura,Michael I. Nishimura,Michael I. Nishimura +19 more
TL;DR: The results suggest that HCV TCR-engineered antigen-reactive T cells may be a plausible immunotherapy option to treat HCV-associated malignancies, such as HCC.
HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer.
Kendra C. Foley,Timothy T. Spear,David C. Murray,Kaoru Nagato,Elizabeth Garrett-Mayer,Michael I. Nishimura +5 more
TL;DR: Of the TCRs tested, T cells expressing the murine Cβ2 TCR or leucine zipper TCR have the highest levels of expression and the highest percentage of lytic and interferon-γ (IFN-γ)-producing T cells.
20
Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.
Timothy T. Spear,Yuan Wang,Kendra C. Foley,David C. Murray,Gina Scurti,Patricia E. Simms,Elizabeth Garrett-Mayer,Lance M. Hellman,Brian M. Baker,Michael I. Nishimura +9 more
TL;DR: It is found that changes in TCR–pMHC affinity did not always predict or dictate IFNγ release or degranulation by TCR gene-modified T-cells, suggesting that less emphasis might need to be placed on TCR-pM HC affinity as a means of predicting or augmenting the therapeutic potential of TCR genes used in ACT.
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
Tamson V. Moore,Gina Scurti,Matthew DeJong,Siao Yi Wang,Annika Dalheim,Courtney Regan Wagner,Kelli A. Hutchens,Jodi Speiser,Constantine Godellas,Chris Fountain,Jessica Fleser,Tarsem Moudgil,Mallory Thomas,David C. Murray,Brendan D. Curti,Joseph I. Clark,Bernard A. Fox,Bernard A. Fox,Michael I. Nishimura +18 more
TL;DR: In this article, a clinical trial was conducted on seven metastatic melanoma patients with autologous T-cells transduced to express a tyrosinase-reactive T-cell receptor (TCR) (TIL 1383I) and truncated CD34 molecule as a selection marker.
7
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.
Timothy T. Spear,Timothy P. Riley,Gretchen E. Lyons,Gretchen E. Lyons,Glenda G. Callender,Glenda G. Callender,Jeffrey J. Roszkowski,Yuan Wang,Patricia E. Simms,Gina Scurti,Kendra C. Foley,David C. Murray,Lance M. Hellman,Rachel H. McMahan,Makio Iwashima,Elizabeth Garrett-Mayer,Hugo R. Rosen,Brian M. Baker,Michael I. Nishimura,Michael I. Nishimura +19 more
TL;DR: It is proposed that T cells harboring cross‐reactive T CRs could serve as a therapeutic agent in these instances and a better understanding of such TCRs’ promiscuous behavior may allow for exploitation of these properties to develop novel, adoptive T cell‐based therapies for viral infections and cancers exhibiting similar genomic instability.